Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
Publication/Presentation Date
3-1-2007
Abstract
The importance of somatic TP53 mutations and germline TP53 codon 72 genotype in the survival of women with epithelial ovarian cancer is controversial. Recent data suggest that a promoter polymorphism in the MDM2 gene may influence age of cancer onset in a gender-specific fashion. We sought to determine the relationship between somatic TP53 mutations, germline genotypes at TP53 codon 72 and MDM2 SNP309, and overall survival and response to chemotherapy in a large series of patients with ovarian and peritoneal carcinomas. Of the 188 cancers, 103 (54.8%) had a TP53 mutation, of which 71% were missense mutations and 29% were null mutations. TP53 mutation status and mutation type (null vs. missense) did not influence response to therapy or overall survival. Women with the codon 72 Pro/Pro had a decreased overall survival (median, 29 months) compared with women with one or two arginine alleles (median, 49 months; P=0.04). Somatic mutation or deletion was equally common for either codon 72 allele. Age of diagnosis was not influenced by codon 72 but showed a trend for younger age in women with somatic TP53 mutations and the MDM2 G/G genotype.
Volume
46
Issue
3
First Page
239
Last Page
247
ISSN
1045-2257
Published In/Presented At
Galic, V., Willner, J., Wollan, M., Garg, R., Garcia, R., Goff, B. A., Gray, H. J., & Swisher, E. M. (2007). Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes, chromosomes & cancer, 46(3), 239–247. https://doi.org/10.1002/gcc.20407
Disciplines
Medicine and Health Sciences
PubMedID
17171684
Department(s)
Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Residents, Fellows and Residents
Document Type
Article
